MX387814B - Síntesis de inhibidor de mcl-1. - Google Patents

Síntesis de inhibidor de mcl-1.

Info

Publication number
MX387814B
MX387814B MX2019011468A MX2019011468A MX387814B MX 387814 B MX387814 B MX 387814B MX 2019011468 A MX2019011468 A MX 2019011468A MX 2019011468 A MX2019011468 A MX 2019011468A MX 387814 B MX387814 B MX 387814B
Authority
MX
Mexico
Prior art keywords
synthesis
mcl
inhibitor
compound
disclosed
Prior art date
Application number
MX2019011468A
Other languages
English (en)
Spanish (es)
Other versions
MX2019011468A (es
Inventor
Alexander Hird
Andrew Stark
Cati Ferrar
Craig Stewart
Debasis Hazra
Jan Koek
Qing Ye
Simon Hardy
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019011468A publication Critical patent/MX2019011468A/es
Publication of MX387814B publication Critical patent/MX387814B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72Hydrazones
    • C07C251/74Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2019011468A 2017-03-31 2018-03-29 Síntesis de inhibidor de mcl-1. MX387814B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479493P 2017-03-31 2017-03-31
PCT/EP2018/058056 WO2018178227A1 (en) 2017-03-31 2018-03-29 Synthesis of mcl-1 inhibitor

Publications (2)

Publication Number Publication Date
MX2019011468A MX2019011468A (es) 2019-11-01
MX387814B true MX387814B (es) 2025-03-04

Family

ID=61827753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011468A MX387814B (es) 2017-03-31 2018-03-29 Síntesis de inhibidor de mcl-1.

Country Status (16)

Country Link
US (1) US11149024B2 (enExample)
EP (1) EP3601230B1 (enExample)
JP (1) JP7032428B2 (enExample)
KR (1) KR102604876B1 (enExample)
CN (1) CN110536884B (enExample)
AR (1) AR111304A1 (enExample)
AU (1) AU2018244180B2 (enExample)
CA (1) CA3056712A1 (enExample)
CO (1) CO2019010035A2 (enExample)
EA (1) EA038226B1 (enExample)
ES (1) ES2909751T3 (enExample)
IL (1) IL269410B2 (enExample)
MX (1) MX387814B (enExample)
TW (1) TWI781996B (enExample)
WO (1) WO2018178227A1 (enExample)
ZA (1) ZA201905645B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
US12319703B2 (en) 2019-01-23 2025-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrazoles as Mcl-1 inhibitors
KR20220024694A (ko) 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
WO2021005043A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021099579A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as mcl-1 inhibitors
MX2022006180A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
JP2023514364A (ja) 2020-02-21 2023-04-05 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1の阻害剤としての大環状インドール誘導体
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
MX2022015998A (es) * 2020-06-19 2023-04-12 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.
WO2021255257A1 (en) 2020-06-19 2021-12-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CA3184877A1 (en) 2020-07-08 2022-01-13 Benoit Christian Albert Ghislain De Boeck Macrocyclic ether containing indole derivatives as inhibitors of mcl-1
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
JP2023553719A (ja) 2020-12-17 2023-12-25 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1阻害剤としての分岐大環状4-(ピラゾール-5-イル)-インドール誘導体
JP2024506648A (ja) 2021-02-12 2024-02-14 ヤンセン ファーマシューティカ エヌ.ベー. がんの治療のためのmcl-1阻害剤としての大環状1,3-架橋6-クロロ-7-ピラゾール-4-イル-1h-インドール-2-カルボキシレート及び6-クロロ-7-ピリミジン-5-イル-1h-インドール-2-カルボキシレート誘導体
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915811A1 (en) * 2014-03-04 2015-09-09 Centre Régional de Lutte contre le Cancer - Centre François Baclesse MCL-1 modulating compounds for cancer treatment
US9949965B2 (en) * 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
MX386103B (es) * 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
CN106478606B (zh) * 2016-09-21 2019-05-10 沈阳药科大学 N-取代吲哚类衍生物及其应用

Also Published As

Publication number Publication date
BR112019019686A2 (pt) 2020-04-14
CA3056712A1 (en) 2018-10-04
CO2019010035A2 (es) 2019-09-30
US20210122735A1 (en) 2021-04-29
IL269410A (en) 2019-11-28
ZA201905645B (en) 2020-05-27
KR102604876B1 (ko) 2023-11-22
EA201992235A1 (ru) 2020-02-10
MX2019011468A (es) 2019-11-01
AU2018244180A1 (en) 2019-11-07
TW201902868A (zh) 2019-01-16
KR20190136039A (ko) 2019-12-09
CN110536884A (zh) 2019-12-03
TWI781996B (zh) 2022-11-01
AR111304A1 (es) 2019-06-26
JP7032428B2 (ja) 2022-03-08
EP3601230A1 (en) 2020-02-05
EP3601230B1 (en) 2022-01-26
EA038226B1 (ru) 2021-07-27
JP2020515557A (ja) 2020-05-28
IL269410B2 (en) 2023-03-01
CN110536884B (zh) 2023-05-02
WO2018178227A1 (en) 2018-10-04
ES2909751T3 (es) 2022-05-10
US11149024B2 (en) 2021-10-19
AU2018244180B2 (en) 2021-03-04
IL269410B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
MX387814B (es) Síntesis de inhibidor de mcl-1.
EP3739476A4 (en) SPEECH SYNTHESIS PROCESS FROM MULTILINGUAL TEXT
CL2018002993A1 (es) Robot empacador.
HUE055242T2 (hu) Omecamtiv mecarbil szintézise
ECSDI17072109S (es) Recipiente contenedor (iii)
MX2020009149A (es) Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos.
MX386478B (es) Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
MX2018009794A (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
AR105967A1 (es) Sales de un inhibidor de pim quinasa
MX373603B (es) Activador de canales de kcnq2-5.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
ECSDI17044309S (es) Mandolina
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
BR112018001451A2 (pt) compostos úteis para a inibição de ror-gama-t
ECSDI17052034S (es) Cantimplora
EP3763637A4 (en) AEROSOL PRODUCT
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
EA201892051A1 (ru) Фармацевтические композиции для лечения злокачественного новообразования
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
ECSDI18002267S (es) Mandolina
EP3965606A4 (en) BUCKLE ARRANGEMENT
EP3793501A4 (en) FIBER PRODUCT
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
BR112016025473A2 (pt) produto cerâmico resistente ao fogo